Results from Tuesday’s presidential election remain unclear — but that didn’t stop a panel of experts from trying to parse the consequences for the pharmaceutical industry.
At a virtual event hosted by the Massachusetts trade group MassBio Thursday, three panelists were skeptical that either potential president would immediately push aggressive drug pricing legislation. But no one assumed the election would end the issue, either.
“Drug pricing may not be the first and foremost priority of any administration, but I don’t think it goes away,” said Tamar Thompson, vice president of U.S. government affairs at Alexion Pharmaceuticals. “We’re in a place where things have to change.”
About the Author Reprints
